Finance

Lists
Q3 2026 earnings • released • Revenue beat +2.96%
See results
GRFS:NASDAQ
Grifols SA - ADR ADR Class B
$8.56
+0.59%
(+0.050) 1D
$8.63
+0.86% (+0.074)
After hours
Closed: Nov 3, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GRFS...
Open
$8.56
High
$8.72
Low
$8.40
Mkt. cap
7.44B
Avg. vol.
743.90K
Volume
1.00M
Dividend
1.10%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
11.51
52-wk high
$9.90
52-wk low
$6.96
EPS
$0.74
Beta
0.75
Shares outstanding
261.42M
No. of employees
25K
Open
$8.56
High
$8.72
Low
$8.40
Mkt. cap
7.44B
Avg. vol.
743.90K
Volume
1.00M
Dividend
1.10%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
11.51
52-wk high
$9.90
52-wk low
$6.96
EPS
$0.74
Beta
0.75
Shares outstanding
261.42M
No. of employees
25K
News stories
From web sources and news partners
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA - ADR ADR Class B
CEONacho Abia
Employees25K
FoundedNov 18, 1940
Headquarters-
SectorBiotechnology
Industry-
Websitegrifols.com
Analyst ratings
Based on 1 analyst giving stock ratings to GRFS in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for GRFS in the last 3 months
Highest
Current $8.56
$9.00 (+5.14%)
Average
$9.00 (+5.14%)
Lowest
$9.00 (+5.14%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sophia Graeff Buhl-Nielsen
J.P. Morgan
Hold
Reiterated
$9.00
+5.1%
10/26/2026
Last report
Nov 2, 2026
Fiscal period
Q3 2026
- / €0.30
Revenue / Est. (EUR)
2.04B / 1.98B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.87B
1.98B
1.70B
1.87B
Cost of goods sold
1.11B
1.28B
1.06B
1.19B
Cost of revenue
1.11B
1.28B
1.06B
1.19B
Research and development expenses
97.01M
90.82M
90.00M
86.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
273.76M
262.86M
269.00M
301.00M
Operating expense
370.34M
353.11M
359.00M
387.00M
Total operating expenses
1.48B
1.63B
1.42B
1.58B
Operating income
381.18M
347.38M
280.00M
298.00M
Other non operating income
-
-33.00M
-
-13.00M
EBT including unusual items
198.13M
111.10M
112.00M
247.00M
EBT excluding unusual items
227.20M
183.10M
143.00M
216.00M
Income tax expense
54.71M
-14.68M
24.00M
64.00M
Effective tax rate
27.61%
-13.21%
21.43%
25.91%
Other operating expenses
-430.00K
-570.00K
-
-
Net income
126.96M
98.25M
73.00M
154.00M
Net profit margin
6.81%
4.96%
4.29%
8.22%
Earnings per share
-
-
-
-
Interest and investment income
-
36.00M
-
120.00M
Interest expense
-156.07M
-107.99M
-139.00M
-179.00M
Net interest expenses
-156.07M
-71.99M
-139.00M
-59.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
484.03M
422.88M
384.00M
364.00M
Gain or loss from assets sale
-
2.00M
-
-6.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps